NCT04954287View on ClinicalTrials.gov

Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

June 10, 2023

Study Completion Date

June 10, 2023

Conditions
Covid19
Interventions
BIOLOGICAL

CVXGA1 low dose

see arm/group description

BIOLOGICAL

CVXGA1 high dose

see arm/group description

Trial Locations (4)

14642

University of Rochester Medical Center, Rochester

40004

Kentucky Pediatric/ Adult Research, Bardstown

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

75093

Research Your Health, Plano

Sponsors

Lead Sponsor

CyanVac LLC
All Listed Sponsors
lead

CyanVac LLC

INDUSTRY

NCT04954287 - Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents | Biotech Hunter | Biotech Hunter